| scholarly article | Q13442814 |
| P50 | author | George A. Bray | Q20675488 |
| Ralph A. DeFronzo | Q58689309 | ||
| Abbas E Kitabchi | Q62995074 | ||
| P2093 | author name string | Thomas A Buchanan | |
| Robert R Henry | |||
| Ralph A DeFronzo | |||
| Sunder Mudaliar | |||
| Robert E Ratner | |||
| Nicolas Musi | |||
| George A Bray | |||
| Abbas E Kitabchi | |||
| Devjit Tripathy | |||
| Frankie B Stentz | |||
| Peter D Reaven | |||
| Dawn C Schwenke | |||
| Stephen C Clement | |||
| MaryAnn Banerji | |||
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study | Q24633604 | ||
| Association of an intensive lifestyle intervention with remission of type 2 diabetes | Q27347992 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study | Q30533186 | ||
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
| Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW | Q34264630 | ||
| Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program | Q34312885 | ||
| Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
| Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study | Q35841253 | ||
| Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey | Q35976508 | ||
| Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010 | Q37022767 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates | Q37251096 | ||
| Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk | Q37278256 | ||
| (How) can we prevent type 2 diabetes? | Q43834090 | ||
| Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients | Q45050552 | ||
| TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. | Q45244072 | ||
| Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
| Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. | Q51385671 | ||
| Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. | Q51470916 | ||
| The natural history of impaired glucose tolerance in the Pima Indians. | Q51623599 | ||
| Lifetime risk and projected population prevalence of diabetes | Q58007870 | ||
| Hepatic dysfunction associated with troglitazone | Q74366194 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glycobiology | Q899224 |
| P304 | page(s) | 2056-2062 | |
| P577 | publication date | 2016-03-16 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW | |
| P478 | volume | 101 |
| Q37232313 | Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance |
| Q94600515 | Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure |
| Q41640163 | Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease |
| Q50179665 | Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction |
| Q90655369 | Regression from prediabetes to normal glucose regulation: State of the science |
| Q88654483 | Roles of Perilipins in Diseases and Cancers |
| Q91492188 | Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES) |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q28073749 | Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk |
Search more.